The current landscape around health data privacy and the promise of synthetic data in healthcare.
The healthcare system generates approximately a trillion gigabytes of data annually, and this amount is doubling every two years. Therefore, the amount of data created over the next three years is likely to be more than the data created over the past 30 years. The ecosystem around this data is complex and constantly trying to build the infrastructure needed to sustain this growth in data.
Landscape around data privacy in healthcare
As the data universe grows in healthcare, so do the opportunities for insight. There have been big leaps in the technology and techniques available for better data analysis. Increased accessibility, increased data and increased granularity is great for innovation. However, this can lead to nervousness of lawmakers, regulators, privacy experts and individuals whose data is involved in these healthcare systems.
Firms that have traditionally used the safe harbor method of de-identification are now looking toward the use of the Expert Determination method for de-identified data and alternative insights. Safe Harbor has limitations in utility and doesn’t have the same, in-depth consideration of risk that Expert Determination methods do. Companies typically have a cautious approach as the shift to Expert Determination can be a big change to current processes, and education and support is needed along the way.
Guaranteeing patient privacy important now more than ever.
Data is the fuel, the glue and the product of the new healthcare ecosystem. Data connectivity is a driving force behind innovation and healthcare transformation. Unfortunately, as connectivity increases, so does risk. As more data is connected, clearer profiles of individuals’ lives start to be built. If this isn’t done with consideration of an individual’s right to privacy, it could erode trust with stakeholders and also (were things to go wrong) potentially have damaging implications to individuals.
The effective support involves advice, education and validation in relation to disclosure risk. Many assume the interaction starts once data has been de-identified. However, the collaboration often start much earlier than that. For example, at Mirador Analytics, we support the development stages of new products, planning for dataset joins or analytics planning to ensure risk mitigation throughout. Our upfront input on disclosure risk helps rollout go more smoothly and better prepares teams for discussions on re-identification risk with vendors and potential customers. Thinking about privacy first enables the integration of automated solutions that reduce time to delivery and also allows teams more time to think about data utility, allowing us to focus on maximizing relevant granularity in an easier way.
Challenges around data de-identification in healthcare.
Data privacy with synthetic data in health care.
Despite different anonymization methods and human expert contributions, today, no technique can guarantee zero risks. However, synthetic data can help healthcare researchers create relatively risk-free data, and therefore, it has a high potential in the healthcare industry in the future.
The most exciting thing about synthetic technology is its adoption. Synthetic data has the potential to improve existing AI algorithms, where protected health information isn’t needed, to make decisions influencing human lives in the future.
As a data de-identification expert, we are already seeing partners utilize synthetic data types in their organizations. However, how its greater adoption will look will be dependent on technological advances and regulatory changes.
Mirador Analytics has partnered with Syntegra, a synthetic healthcare data generation leader, to consider any residual risk in synthetic data generated from protected health information. We’re hoping that our analysis work will lead to the creation of best practice risk-reducing methods of creating synthetic datasets.
Read the full interview with Jamie Blackport, CEO and Founder here >>
Author: Mirador Analytics & Syntegra
Patient Marketing and Privacy
Jamie Blackport, CEO and Founder, talked about how Mirador Analytics creates an optimal balance between patient privacy and data utility for DeepIntent's Patient Modeled Audiences solution and the rest of the healthcare industry.
When it comes to healthcare marketing, stakeholders' concerns about the potential involvement of individuals' health data; therefore, the healthcare marketing companies need to design their processes to protect patient privacy and comply with data privacy regulations.
Regulations like HIPAA, California's CCPA, or the Colorado Privacy Act make people more conscious about their data privacy and give them the power to act if they feel compromised. Moreover, multiple regulations can cause severe challenges for healthcare marketing companies.
Documentation of processes and assessment of risk helps these organizations highlight risk and what they are doing to minimize it. This can help build vital trust factors as entities have implemented necessary safeguards to protect the privacy of sensitive medical information. These assessments can also support the navigation of regulation for companies working hand-in-hand with their legal parties to comply as necessary, and in some cases going beyond.
Mirador Analytics extended Board of Directors.
Mirador Analytics has bolstered its Board of Directors with the addition of two life sciences executives from Thomson Reuters Scientific & Healthcare and Kyowa Kirin International.
Mirador Analytics, the leading HIPAA Expert Determination provider, recently announced the extension of its Board of Directors, adding two prominent life sciences former executives, Shahir Kassam-Adams, Corporate Development at Datavant, former Executive Vice President of Thomson Reuters Scientific & Healthcare, and Dr. Tom Stratford, CEO of Kelso Pharma, former CEO and President of Kyowa Kirin International. The extended Board, which consists of five members, also includes Jamie Blackport, Founder, CEO, and President; Jamie Gray, Chief Operating Officer; and Chris Watson, Head of IT & Security, all of Mirador Analytics.
The two new board members bring broad and deep expertise to the company, which will help guide its future strategy and growth.
Kassam-Adams was co-founder of Universal Patient Key (UPK) – now a part of Datavant. In addition, he has been an operator or early investor in multiple health care technology-enabled start-ups and companies, including Aileron Solutions, Social Safeguard, TGaS, Decision Resources Group (DRG), and Thomson Reuters Scientific & Healthcare. Shahir has an MS in Computer Science from Johns Hopkins University and an MBA from the Wharton School of the University of Pennsylvania.
Stratford is a highly experience life sciences executive with a 25+ year track record in establishing and building businesses across Europe, the Middle East, and the USA. He was one of the first early employees in ProStrakan as it grew to be a public company. Following the acquisition by Kyowa Kirin, Tom spent nine years leading the European and US teams as CEO/President with a combined turnover approaching $1bn. Tom currently serves as a NED for Axol Biosciences and CEO of Kelso Pharma.
Blackport has a 20+ year commercial and medical affairs global pharmaceutical career where he specialized in successfully helping small and mid-sized biopharma companies commercially develop, transact, and launch products worldwide. Jamie led the International Marketing and Medical Affairs of Kyowa Kirin International and AstraZeneca. He started Mirador Analytics with his fellow founders as they recognized health care organizations needed support to realize the full potential of their data and analyses. Offering that support would, in turn, help support innovation and growth in the industry and advance global health care.
About Mirador Analytics
Mirador Analytics supports organizations across the health care ecosystem to ensure the privacy of individuals is protected through expert evaluation of data de-identification and the use of proprietary software solutions. Mirador Analytics aims to achieve high levels of privacy for individuals while maximizing data utility to allow for innovation, efficiency, and development in health care. For more information, visit www.miradoranalyitcs.com
Jamie Blackport, firstname.lastname@example.org
Eszter Vuity, email@example.com
Syntegra Partners with Mirador Analytics to Certify Industry-Wide Privacy Metrics for Synthetic Data
SAN FRANCISCO, CA and WILMINGTON, DE, [Date TBD] – Today, Syntegra, a leader in synthetic healthcare data generation, and Mirador Analytics, the leading HIPAA expert determination provider, announced a partnership to certify Syntegra’s metrics for validating the privacy of synthetic data. This partnership is another step forward in both companies’ broader goal of enabling easier, faster and safer access to healthcare data to advance research efforts.
Syntegra is working with Mirador to review and certify Syntegra’s privacy techniques used to validate that their synthetic data fully protects patient privacy, ensuring no patient can be re-identified via the synthetic data. Once the project is complete later this year, the companies plan to publish materials that will support application and understanding of these privacy-preserving techniques for a wider audience to aid industry thought-leadership/guidelines.
Syntegra is leading the creation of privacy metrics for synthetic data, enabling synthetic healthcare data to be clearly assessed by any organization within a risk and privacy governance structure they already understand. Through this work, Syntegra and Mirador are paving the way for standard, industry-wide metrics to ensure patient privacy while enabling greater usage and value of healthcare data.
Maintaining patient privacy is paramount, but the industry must discover better ways of securely sharing and accessing patient data to advance the field of medicine, and synthetic data is an important mechanism to address this need. Rather than assuming synthetic data is inherently private simply because it’s synthetic, Syntegra is taking it a further step by partnering with Mirador to certify their metrics. This is particularly important when synthetic data is generated from actual health records.
“Any medical innovation requires evidence, and evidence requires data. To improve outcomes, it is imperative that we find new ways of leveraging healthcare data while protecting patient privacy,” said Michael D. Lesh, MD, founder and CEO of Syntegra. “We’re thrilled to partner with Mirador to help prove that Syntegra-generated synthetic data successfully prevents disclosure of patient information.”
"With the current industry focus on big data in healthcare, the amount of data created in the next three years is expected to be more than the data created over the past three decades. There’s always a residual risk to privacy in data, and with exponential growth expected, we must explore all techniques we have available to us to minimize risk while absorbing the utility. - Said Jamie Blackport, CEO and Founder of Mirador Analytics. "We're thrilled to work with Syntegra to help them define better industry-standards of synthetic data metrics we hope to be a game-changer in data privacy protection in the future."
Prognos Health and Mirador Analytics Form Strategic Partnership to Streamline Expert Determination for Patient-Level Data
New York, NY (June 22, 2021) — Prognos Health, a leading healthcare analytics platform company, and Mirador Analytics, the leading HIPAA expert determination provider, today announced a strategic partnership to provide Prognos clients with a more streamlined end-to-end HIPAA certification process that reduces risk.
“At Prognos we are committed to maintaining the highest level of privacy and security for our data and our technology. This partnership with Mirador is an extension of that promise,” said Jason Bhan, MD, co-founder and chief medical officer, Prognos Health. “By working with Mirador to integrate their leading expert determination services and support into our prognosFACTORⓇ platform, our clients can be assured that our analytics or data purchase options on our marketplace are fully de-identified and compliant with HIPAA privacy regulations.”
By partnering with Mirador Analytics, Prognos is able to utilize a suite of programmatic tests to assess the risk of re-identification in healthcare datasets, tools to determine dataset compliance, and have access to an automated approach to removing elements that present any potential risk of re-identification.
“At Mirador, we understand that organizations need more agile access and greater value from healthcare data and so we help them to innovate and improve care quality without compromising compliance and patient confidentiality. We’re excited to partner with Prognos because they have something unique – the ability to link lab test result data with other more traditional and emerging datasets at scale,” shared Jamie Blackport, founder and chief executive officer, Mirador Analytics. “We look forward to expanding our partnership to accelerate our expert-led risk monitoring automation processes within the Prognos environment.”
To continue improving scalability, Prognos Health and Mirador Analytics seek to further develop the partnership in the future to provide an even faster, more automated process using a SaaS model embedded within Prognos Health’s prognosFACTOR platform.
Winners of COVID-19 Research Accelerator Grants Announced
Congratulations to the 15 winners of the first Research Accelerator grants, funded by the Bill & Melinda Gates Foundation! We are very proud to support this initiative, and we look forward to seeing the research outputs.
The Accelerator Program has received hundreds of applications from every corner of the globe. The awardees will find evidence for policies that mitigate the effects of the current pandemic and strengthen future disaster preparedness. The projects will leverage the COVID-19 Research Database with more than 250 million unique patients and 85 billion records. The Database is the largest HIPAA-compliant, de-identified, and limited patient-level data sets of real-world data. Read more: Winners of COVID-19 Research Accelerator Grants Announced (globenewswire.com)
Life after the COVID-19 outbreak
Our team has celebrated Mirador Day recently with much fun and outdoor activities which they kindly shared with us. They went cycling, camping, and walking; they visited their old universities and friends. Others enjoyed some lovely family time with their kids, both indoors and outdoors.
Our team is the heart of our business; they are our superstars. We are dedicated to protecting them from the risk of infection and helping them stay physically and mentally healthy.
Author: Eszter Vuity
We are thrilled to share the news of the $1m Research Accelerator program announced by the COVID-19 Research Database Consortium today. The fund is available for research teams leveraging real-world data available to inform medical interventions and targeted mitigation policies.
The COVID-19 Research Database, with 1,500 researchers and over 100 studies in progress, is the largest HIPAA-compliant dataset available to public health and policy researchers, enabling them to further their investigations of the direct and indirect effects of the COVID-19 pandemic on population health and economics.
We are grateful to all our partners for making this world-changing opportunity available. Big thank you to AnalyticsIQ, Change Healthcare, Elsevier, Glooko, Health Care Cost Institute, Healthjump, HealthWise Data, Medidata Solutions, Datavant, MUNICH RE US LIFE CORPORATION, Office Ally, Ovation, PointClickCare, QIAGEN, SAS, Snowflake, STATA, Symphony Health, Veradigm, and Eurofins Viracor.
Read press >>
What They Didn’t Teach You About Expert Determination and HIPAA
Register for our upcoming free webinar with Datavant on HIPAA Expert Determination and learn how you can achieve high levels of privacy for individuals while maximizing data utility to allow for innovation, efficiency, and development in health care.
Date: 28 APR 2021, 1 PM EST
We will discuss why Expert Determination is a critical step in using and connecting health data, and we will provide you with an overview of common pitfalls and delays in joining de-identified data across organizations. Furthermore, we will give you some ideas on overcoming these issues and maximizing data utility under HIPAA regulation.
Join Datavant and Mirador to learn about:
Don’t miss the free webinar! There will be a live Q&A at the conclusion of the presentation.
Mirador Analytics Partners with Datavant to Create Step Change in Industry’s Approach to HIPAA De-identification and Certification
Today, Mirador Analytics, the leading HIPAA Expert Determination provider, and Datavant, the leader in helping healthcare organizations safely connect their data while protecting patient privacy, announced a partnership where Mirador Analytics will offer streamlined HIPAA certification services and remediation tools to members of the Datavant ecosystem.
While still having Experts active in performing determinations, the integration of products automates large portions of the certification process, resulting in a much faster end-to-end certification process, while simultaneously protecting data under HIPAA and providing flexibility in which data to preserve.
Under the partnership, Datavant customers who use Mirador’s service receive on-demand certification of new datasets with results returned within 24 hours. The technical integration includes:
“The value of health data is more crucial today than ever before. The huge amounts of data available brings greater privacy risk and there is a concern of bottlenecks in assessing this risk in deidentified data.” said Jamie Blackport, Founder and Chief Executive Officer of Mirador. “Current approaches are either slow, taking months to certify a single new combination of data; or they are generic, assuming that one certified data layout will meet all customer needs which has potential for increased risk and reduces data utility. Through our partnership with Datavant, we are eager to offer the Datavant ecosystem an approach to certification that is fast, simple, risk-reducing, and fit-for-purpose, allowing customers to spend less time focused on the certification process and more time providing valuable analytics and insights on top of de-identified, certified health data.”
“We are thrilled to announce our expanded partnership with Mirador,” said Travis May, Founder and Chief Executive Officer of Datavant. “We have worked with the Mirador team for years, and have been continuously impressed with their ability to provide reliable, high-quality statistical certification at the speed of business. The preservation of patient privacy is critical to the ethical and trusted use of patient data, and we expect that this new partnership will reset the bar for privacy-preservation across the industry -- while allowing more data to be safely connected for patient benefit.”
Media Contact: Jamie Gray, firstname.lastname@example.org